On November 6, Revolution Medicines, Inc. rose 6.56% in Regular Trading, trading at $184.81 per share, with turnover of $46.2321 million.
The move followed continued support from Wall Street after the company’s recent quarterly report, with RBC raising its price target to $321 from $260 and maintaining an Outperform rating.
Earlier, Revolution Medicines, Inc. reported quarterly EPS of $(1.90), better than the consensus estimate of $(2.42), while revenue reached $197.559 million, far above market expectations. Recent company updates also pointed to strong early commercialization for RASONQUE after its August approval, including positive prescription conversion, payer access and physician uptake, alongside ongoing Phase 3 combination studies that reinforce medium-term growth expectations.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments